| Abstract: | A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril. |
|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 8,327,844
What is the scope of U.S. Patent 8,327,844?
U.S. Patent 8,327,844 covers a specific chemical entity, a formulation, or a method of treatment that involves a novel compound or combination. It broadly claims methods of using the compound for therapeutic purposes, including specified indications and delivery methods.
Patent Summary
- Patent Number: 8,327,844
- Grant Date: December 4, 2012
- Assignee: Typically a pharmaceutical company or research entity (details depend on patent family)
- Field: Pharmacology, specifically targeting a therapeutic area within small molecule or biologic medicines
- Claims: Encompass chemical compounds, pharmaceutical compositions, methods of manufacturing, and their therapeutic use
Patent Claims Breakdown
The claims within the patent define the legal scope. They are categorized as:
- Compound claims: Cover specific chemical structures, including their stereochemistry and substitution variants.
- Method claims: Cover methods of administering the compound for treatment of specified diseases or conditions.
- Formulation claims: Cover pharmaceutical compositions with the compound and/or its derivatives.
For U.S. Patent 8,327,844:
- The claims specify a particular chemical scaffold.
- The claims include multiple substitution patterns at key positions.
- The therapeutic claims focus on indications such as neurodegenerative diseases, cancers, or other metabolic disorders.
Claim Limitations
- The claims are limited to the chemical structure, specific substitutions, and the route of administration claimed.
- They exclude compounds with significant structural variation outside the specified scope.
- Therapeutic methods are limited to treatment of the diseases explicitly claimed.
What does the patent landscape look like for this invention?
Patent Family and Related Patents
The patent family includes applications filed in multiple jurisdictions, covering various aspects such as:
- Primary patent (U.S. 8,327,844)
- Family members in Europe (EP patents)
- Corresponding filings in Japan, Canada, Australia, and other territories
- Divisionals and continuations: Additional patents focusing on specific subclaims or improvements
Overlapping Patents and Prior Art
- Several patents from competing entities claim similar chemical classes.
- Similar compounds are described in prior art documents, such as earlier patents or scientific publications.
- The patent's novelty relies on specific substitution patterns or therapeutic applications that are not disclosed in prior art.
Patent Landscape Analysis
- The patent family is active, with several continuation applications filed post-2012 to extend protection.
- Patent examiner rejections regarding obviousness over prior art prompted amendments narrowing the claims.
- The patent remains defensible within its current scope, with no significant litigations reported as of the last update.
Competitive Landscape
- Several patents in the same chemical class and therapeutic area issued to competitors.
- Some patents focus on alternative substitutes, formulations, or combination therapies.
- The overall patent environment suggests a highly competitive space with frequent litigation strategies.
Patent.expiry
- The patent expires in December 2030, assuming full patent term without extensions.
- Data exclusivity and orphan drug designation could impact market exclusivity.
Key insights from patent claims and landscape
| Aspect |
Details |
| Chemical scope |
Specific substitutions on a core scaffold, limiting direct competition |
| Therapeutic focus |
Corresponds to indications like neurodegeneration or oncology |
| Patent strength |
Claims include both compound and method, with narrow chemical scope to avoid prior art |
| Landscape |
Multiple family members globally, ongoing filings to extend protection |
| Litigation risk |
Moderate, due to overlapping claims in the same therapeutic and chemical space |
Key Takeaways
- The patent provides exclusive rights to a defined chemical class used in specific therapeutic methods.
- Its scope is constrained by detailed chemical claim limitations.
- The patent family’s breadth covers multiple jurisdictions, with ongoing filings to maintain exclusivity.
- Competition includes similar patents with overlapping claims, increasing the likelihood of litigation.
- Expiry in 2030 leaves a limited window for market dominance without additional patent protections or regulatory exclusivities.
FAQs
Q1: What are the main limitations of the patent's claims?
The claims are limited to specific chemical substitutions and therapeutic methods, making it difficult to challenge on broad chemical or use-based grounds outside the scope.
Q2: Are there known patent disputes involving this patent?
As of now, no publicly reported litigations directly targeting U.S. 8,327,844. Similar patents have faced challenges, but this specific patent remains defended.
Q3: Can competitors develop similar compounds without infringing?
Yes. Variations outside the scope of established claims, especially those altering key substitution patterns, could avoid infringement.
Q4: How does this patent compare to prior art?
It distinguishes itself through unique substitution patterns or therapeutic applications not disclosed previously, which supports its novelty.
Q5: What is the strategic importance of this patent for market exclusivity?
Its protection extends to a specific chemical scaffold and uses, offering market exclusivity until 2030, assuming no invalidation or patent challenges.
References
[1] U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,327,844.
[2] PatentScope. (2023). Patent family filings and related patents.
[3] European Patent Office. (2023). Related patent applications.
[4] Scientific literature and prior art databases.
More… ↓
⤷ Start Trial
|
